Quidel Corp

Quidel Corp Stock Forecast & Price Prediction

Live Quidel Corp Stock (QDEL) Price
$43.75

7

Ratings

  • Buy 5
  • Hold 2
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$43.75

P/E Ratio

-291.67

Volume Traded Today

$2.5M

Dividend

Dividends not available for QDEL

52 Week High/low

75.86/29.74

Quidel Corp Market Cap

$2.94B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $QDEL ๐Ÿ›‘

Before you buy QDEL you'll want to see this list of ten stocks that have huge potential. Want to see if QDEL made the cut? Enter your email below

QDEL Summary

Based on ratings from 7 stock analysts, the Quidel Corp stock price is expected to increase by 28.39% in 12 months. This is calculated by using the average 12-month stock price forecast for Quidel Corp. The lowest target is $44 and the highest is $64. Please note analyst price targets are not guaranteed and could be missed completely.

QDEL Analyst Ratings

About 7 Wall Street analysts have assignedQDEL 5 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Quidel Corp to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on QDEL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

QDEL stock forecast by analyst

These are the latest 20 analyst ratings of QDEL.

Analyst/Firm

Rating

Price Target

Change

Date

John Sourbeer
UBS

Neutral

$50

Upgrade

Sep 19, 2024
Alexander Nowak
Craig-Hallum

Buy

$57

Upgrade

Sep 5, 2024
Conor McNamara
RBC Capital

Outperform

$61

Reiterates

Aug 16, 2024
Conor McNamara
RBC Capital

Outperform

$61

Reiterates

Aug 1, 2024
Conor McNamara
RBC Capital

Outperform

$68

Maintains

May 9, 2024
John Sourbeer
UBS

Sell

$42

Downgrade

Mar 4, 2024
Andrew Brackmann
William Blair

Market Perform


Downgrade

Feb 14, 2024
Alexander Nowak
Craig-Hallum

Hold


Downgrade

Feb 14, 2024
Conor McNamara
RBC Capital

Outperform

$81

Maintains

Feb 14, 2024
Casey Woodring
JP Morgan

Underweight

$37

Downgrade

Feb 14, 2024
Andrew Cooper
Raymond James

Outperform

$76

Downgrade

Feb 14, 2024
Conor McNamara
RBC Capital

Outperform

$130

Maintains

Dec 21, 2023
Patrick Donnelly
Citigroup

Neutral

$72

Downgrade

Dec 11, 2023
Andrew Cooper
Raymond James

Strong Buy

$100

Maintains

Nov 2, 2023
Conor McNamara
RBC Capital

Outperform

$140

Reiterates

Sep 19, 2023

Raymond James

Strong Buy


Maintains

Aug 15, 2023

JP Morgan

Neutral


Maintains

Aug 9, 2023

RBC Capital

Outperform


Reiterates

Aug 9, 2023
Conor McNamara
RBC Capital

Outperform

$133

Maintains

May 4, 2023
Andrew Cooper
Raymond James

Strong Buy

$130

Maintains

Feb 16, 2023

QDEL Company Information

What They Do: Provides diagnostic testing solutions.

Business Model: QuidelOrtho Corporation generates revenue through various business units that offer a range of diagnostic testing products. The company sells clinical chemistry instruments, immunoassay tests, blood typing equipment, and molecular diagnostics directly to healthcare providers and through distributors, targeting hospitals, laboratories, and point-of-care settings.

Other Information: Founded in 1979 and based in San Diego, California, QuidelOrtho operates globally, with a presence in North America, Europe, the Middle East, Africa, and China. The company focuses on innovative diagnostic solutions to aid in disease detection and management across multiple therapeutic areas.
QDEL
Quidel Corp (QDEL)

When did it IPO

1992

Staff Count

7,100

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Brian J. Blaser

Market Cap

$2.94B

Quidel Corp (QDEL) Financial Data

In 2023, QDEL generated $3.00B in revenue, which was a decrease of -8.21% from the previous year. This can be seen as a signal that QDEL's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$1.66B

Revenue From 2021

$1.70B

2.22 %
From Previous Year

Revenue From 2022

$3.27B

92.28 %
From Previous Year

Revenue From 2023

$3.00B

-8.21 %
From Previous Year
  • Revenue TTM $2.82B
  • Operating Margin TTM 7.1%
  • Gross profit TTM $1.49B
  • Return on assets TTM 1.0%
  • Return on equity TTM -45.8%
  • Profit Margin -66.2%
  • Book Value Per Share 47.35%
  • Market capitalisation $2.94B
  • Revenue for 2021 $1.70B
  • Revenue for 2022 $3.27B
  • Revenue for 2023 $3.00B
  • EPS this year (TTM) $-31.25

Quidel Corp (QDEL) Latest News

News Image

Fri, 08 Nov 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - The healthcare diagnostics specialist surpassed earnings expectations, achieving better-than-anticipated profits despite a minor decline in revenue.

Why It Matters - Exceeding earnings expectations amid a revenue drop indicates strong management and operational efficiency, potentially boosting investor confidence and stock performance.

News Image

Fri, 08 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - QDEL's Q3 results show growth in non-respiratory revenues and reduced operating expenses year-over-year, but gross margins have declined.

Why It Matters - QDEL's growth in non-respiratory revenues and reduced operating expenses indicate operational efficiency, but declining gross margins may signal potential profitability concerns for investors.

News Image

Thu, 07 Nov 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - QuidelOrtho Corporation (NASDAQ: QDEL) will hold its Q3 2024 earnings conference call on November 7, 2024, at 5:00 PM ET. Key executives will present financial results.

Why It Matters - QuidelOrtho's Q3 earnings call indicates financial performance insights, which can influence stock valuation and investor sentiment based on earnings results and future guidance.

News Image

Thu, 07 Nov 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - QuidelOrtho Corporation reported solid financial results for Q3 2024, highlighting growth and margin improvement aligned with its strategic priorities.

Why It Matters - QuidelOrtho's solid Q3 results indicate effective strategic execution, suggesting potential growth and improved margins, which can positively impact stock performance and investor sentiment.

News Image

Thu, 07 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - QuidelOrtho (QDEL) reported Q3 earnings of $0.85 per share, surpassing the Zacks Consensus Estimate of $0.31, but down from $0.90 per share a year earlier.

Why It Matters - QuidelOrtho's significant earnings beat signals strong performance and potential growth, despite a slight year-over-year decline, impacting investor sentiment and stock valuation.

News Image

Thu, 31 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL), which may impact shareholder interests.

Why It Matters - The investigation into QuidelOrtho's officers and directors for potential fiduciary breaches could lead to legal repercussions, affecting stock performance and shareholder value.

...

QDEL Frequently asked questions

The highest forecasted price for QDEL is $64 from at .

The lowest forecasted price for QDEL is $44 from from

The QDEL analyst ratings consensus are 5 buy ratings, 2 hold ratings, and 0 sell ratings.